Expertise in
40
conditions

Dr. Deborah J. Wong

The Regents Of The University Of California
Los Angeles, CA
Expertise in
40
conditions
Specialties:Hematology | Oncology
Offers Telehealth
Expertise in
40
conditions
OverviewInsuranceLocationsClinical Research

Overview

Deborah Wong is a Hematologist and an Oncologist in Los Angeles, California. Dr. Wong is highly rated in 40 conditions, according to our data. Her top areas of expertise are Lung Cancer, Inflammatory Breast Cancer, Nasopharyngeal Carcinoma, and Oral Squamous Cell Carcinoma.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Torrance Memorial Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
200 Ucla Medical Plz, Suite 165 34, Los Angeles, CA 90095
310-824-8403
Other Locations
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 210, Santa Monica, CA 90404
310-458-2381
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
3445 Pacific Coast Hwy, Suite 300, Torrance, CA 90505
310-325-8252
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
900 Weyburn Place, Suite 14 171, Los Angeles, CA 90095
310-825-8173
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
6633 Telephone Rd, Ventura, CA 93003

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
A Phase 1/2, Open-Label, Study to Evaluate the Safety and Anti-Tumor Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, as a Monotherapy and in Combination With Paclitaxel, in Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug
Study Drug: FS118
Study Phase: Phase 1/Phase 2
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin
Enrollment Status: Terminated
Publish Date: June 24, 2024
Intervention Type: Drug
Study Drug: Rivoceranib
Study Phase: Phase 2
An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: April 06, 2023
Intervention Type: Drug
Study Drugs: Pembrolizumab, Cetuximab
Study Phase: Phase 2
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: March 20, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

1 Total Publications

A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers.
A human microdose study of the antimalarial drug GSK3191607 in healthy volunteers.
Journal: British journal of clinical pharmacology
Published: August 11, 2017
Similar Doctors
Expertise in
26
conditions
Dr. Sant P. Chawla
Hematology | Oncology | Pain Medicine
Expertise in
26
conditions
Dr. Sant P. Chawla
Hematology | Oncology | Pain Medicine
2811 Wilshire Blvd, Suite 414, 
Santa Monica, CA 
 (2.5 mi)
310-552-9999
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sant Chawla is a Hematologist and an Oncologist in Santa Monica, California. Dr. Chawla is highly rated in 26 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Myxoid Liposarcoma, and Synovial Sarcoma.

Expertise in
7
conditions
Dr. James R. Berenson
Hematology | Oncology
Expertise in
7
conditions
Dr. James R. Berenson
Hematology | Oncology
9201 W Sunset Blvd, Suite 310, 
West Hollywood, CA 
 (3.5 mi)
310-623-1222
Languages Spoken:
English
Offers Telehealth

James Berenson is a Hematologist and an Oncologist in West Hollywood, California. Dr. Berenson is highly rated in 7 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Bone Tumor, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Vertebroplasty.

Expertise in
24
conditions
Dr. Alexandra Drakaki
Hematology | Oncology
Expertise in
24
conditions
Dr. Alexandra Drakaki
Hematology | Oncology

The Regents Of The University Of California

200 Ucla Medical Plz, Suite B265, 
Los Angeles, CA 
310-825-0128
Languages Spoken:
English
Offers Telehealth

Alexandra Drakaki is a Hematologist and an Oncologist in Los Angeles, California. Dr. Drakaki is highly rated in 24 conditions, according to our data. Her top areas of expertise are Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Bone Marrow Aspiration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile